Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. [electronic resource] by
- Bianchini, D
- Omlin, A
- Pezaro, C
- Lorente, D
- Ferraldeschi, R
- Mukherji, D
- Crespo, M
- Figueiredo, I
- Miranda, S
- Riisnaes, R
- Zivi, A
- Buchbinder, A
- Rathkopf, D E
- Attard, G
- Scher, H I
- de Bono, J
- Danila, D C
Producer: 20140106
In:
British journal of cancer vol. 109
Availability: No items available.
|